Alnylam Pharmaceuticals, Inc. vs Hasbro, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Hasbro, Inc. trades at $97.48 (market cap $13.69B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.2× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 2.89% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HAS | |
|---|---|---|
Market Cap | $29.60B | $13.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $105.88 |
52-Week Low | $205.48 | $70.95 |
Enterprise Value | $27.56B | $15.88B |
Dividend Yield | — | 2.89% |
Trailing returns across standard periods
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →